Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) fell 4.1% during trading on Friday . The company traded as low as $3.00 and last traded at $3.01, with a volume of 609,793 shares. The stock had previously closed at $3.14.

A number of brokerages recently commented on AVXL. FBR & Co reaffirmed an “outperform” rating and issued a $10.00 price target on shares of Anavex Life Sciences Corp. in a research note on Monday, August 15th. Maxim Group set a $15.00 price target on Anavex Life Sciences Corp. and gave the stock a “buy” rating in a research note on Wednesday, July 27th. Finally, Zacks Investment Research lowered Anavex Life Sciences Corp. from a “buy” rating to a “hold” rating in a research note on Tuesday, July 12th.

The stock’s market capitalization is $108.56 million. The company’s 50-day moving average is $4.76 and its 200 day moving average is $4.77.

Anavex Life Sciences Corp. (NASDAQ:AVXL) last released its quarterly earnings results on Thursday, August 11th. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.03. On average, equities research analysts forecast that Anavex Life Sciences Corp. will post ($0.34) EPS for the current fiscal year.

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.